Skip to main content

Takeda Announces Strategic Leadership Changes to Help Drive Continued Growth and Competitiveness in Global Marketplace

Written by: Editor
Published on: 3 Feb 2022

Takeda Announces New AppointmentOSAKA, Japan and CAMBRIDGE, Massachusetts, February 3, 2022 –Takeda (TSE:4502/NYSE:TAK) today announced changes to its executive leadership team to continue driving long-term growth in a highly competitive and dynamic global marketplace. The leadership changes, unless otherwise noted, will be effective at the start of Takeda’s fiscal year 2022 (April 1, 2022) and these executives will report to President and CEO Christophe Weber:

  • Gabriele Ricci, who formerly served as Head of IT for the Plasma-Derived Therapies (PDT) Business Unit has been appointed Takeda’s Chief Data and Technology Officer, effective February 1, 2022. In this role, Gabriele will lead the critical transformation of the company’s Data, Digital and Technology division. Elevating and evolving the company’s existing IT function demonstrates the company’s commitment to creating an industry-leading data and technology approach to ultimately help better deliver life-transforming treatments to patients and society.
     
  • Ramona Sequeira, who currently serves as President of the U.S. Business Unit and Global Portfolio Commercialization, has been appointed President, Global Portfolio Division. This newly created division in Takeda will bring together three global teams and three regional businesses to ensure the company can successfully bring new and existing global products to patients. Specifically, Ramona will have oversight over Global Medical, Global Product Launch Strategy, the Vaccine Business Unit as well as three regional business units including Europe and Canada, Growth and Emerging Markets and the China Business Unit.
  • Julie Kim, who is currently President of the PDT Business Unit, has been appointed President of the U.S. Business Unit and U.S. country head. In this role, Julie will focus on continuing to grow Takeda’s business in the U.S., a key market for the company’s success.
  • Giles Platford, who is currently President of the Europe and Canada Business Unit, has been appointed President of the PDT Business Unit, which will remain one of the most important growth drivers of revenue for Takeda over the coming years.

“My executive leadership team has been instrumental in helping to shape Takeda into a global, values-based biopharmaceutical company that delivers transformational medicine to patients around the world. Our strategy is working, and we continue to gain momentum – with competitive scale, a global footprint and a diverse pipeline with approximately 40 new molecular entities in clinical development,” said Christophe Weber, president and CEO, Takeda. “We are looking to the future, with clear goals in mind, including the opportunity to reinforce our global launch capabilities and harness data and digital to revolutionize the patient experience. This is the team that will help take us to the next level and ensure that we continue to grow and evolve.”

In addition, Takeda will expand the roles of other executive team members, including Lauren Duprey, Chief Human Resource Officer, to further focus on employee well-being; Takako Ohyabu, Chief Global Corporate Affairs and Sustainability Officer, to accelerate delivering against our purpose-led sustainability agenda; and Mwana Lugogo, Global Ethics and Compliance, to include data privacy. Takeda will also continue to have a focus on and commitment to its Oncology Business Unit and Japan Business Unit, along with its other critical functional areas such as Research and Development, Finance, Business Development, Human Resources, Quality, Ethics & Compliance, Legal, Global Corporate Affairs, Corporate Strategy and Manufacturing with executive leadership of these areas continuing to report to Mr. Weber.

About Takeda

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.